These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. SOHO State-of-the-Art Updates and Next Questions: A Modern Approach to the Systemic Treatment of Advanced CTCL. Brazel D; Pinter-Brown L Clin Lymphoma Myeloma Leuk; 2023 Jun; 23(6):401-409. PubMed ID: 37061415 [TBL] [Abstract][Full Text] [Related]
6. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL. Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520 [TBL] [Abstract][Full Text] [Related]
7. Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma. Kamstrup MR; Gjerdrum LM; Biskup E; Lauenborg BT; Ralfkiaer E; Woetmann A; Ødum N; Gniadecki R Blood; 2010 Oct; 116(14):2504-12. PubMed ID: 20538790 [TBL] [Abstract][Full Text] [Related]
8. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update. Ramelyte E; Dummer R; Guenova E Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295 [No Abstract] [Full Text] [Related]
10. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969 [TBL] [Abstract][Full Text] [Related]
11. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas. Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic Features of Cutaneous T-Cell Lymphomas With Extracutaneous Metastasis: A Case Series. Tang H; Matsumoto N; Foss F; Xu M; Ahmed A Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):e405-e410. PubMed ID: 37659965 [TBL] [Abstract][Full Text] [Related]
13. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas. Bosisio FM; Cerroni L Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852 [TBL] [Abstract][Full Text] [Related]
14. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome. Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466 [TBL] [Abstract][Full Text] [Related]
15. CD147-Cyclophilin a Interactions Promote Proliferation and Survival of Cutaneous T-Cell Lymphoma. Sakamoto M; Miyagaki T; Kamijo H; Oka T; Boki H; Takahashi-Shishido N; Suga H; Sugaya M; Sato S Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360654 [TBL] [Abstract][Full Text] [Related]
17. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection. Blackmon AL; Pinter-Brown L Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179 [TBL] [Abstract][Full Text] [Related]
18. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). Bunn PA; Foss FM J Cell Biochem Suppl; 1996; 24():12-23. PubMed ID: 8806090 [TBL] [Abstract][Full Text] [Related]
20. Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials. Lai P; Wang Y Cancer Biol Med; 2021 Feb; 18(1):34-51. PubMed ID: 33628583 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]